

Ronald G Hall 2nd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5084745/publications.pdf>

Version: 2024-02-01

64
papers

1,327
citations

361413

20
h-index

361022

35
g-index

64
all docs

64
docs citations

64
times ranked

1754
citing authors

#	ARTICLE	IF	CITATIONS
1	The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts. <i>Antibiotics</i> , 2022, 11, 295.	3.7	2
2	Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 949-950.	2.5	3
3	Do the types and routes of proton pump inhibitor treatments affect Clostridium difficile in ICU patients? A retrospective cohort study. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 399-404.	3.1	2
4	Characterization and compensation of inhomogeneity artifact in spiral hyperpolarized ¹³ C imaging of the human heart. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 157-166.	3.0	8
5	Pharmacists Without Access to the EHR: Practicing with One Hand Tied Behind Our Backs. <i>Innovations in Pharmacy</i> , 2021, 12, 16.	0.6	7
6	Potential Excess Intravenous Antibiotic Therapy in the Setting of Gram-Negative Bacteremia. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 133.	1.6	0
7	Efficacy and benefits of mock residency interviews. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 958-963.	1.0	3
8	Preoperative imaging of glioblastoma patients using hyperpolarized ¹³ C pyruvate: Potential role in clinical decision making. <i>Neuro-Oncology Advances</i> , 2021, 3, vtab092.	0.7	9
9	Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1159, 122354.	2.3	4
10	Effect of Doxorubicin on Myocardial Bicarbonate Production From Pyruvate Dehydrogenase in Women With Breast Cancer. <i>Circulation Research</i> , 2020, 127, 1568-1570.	4.5	21
11	Appropriateness of Fluoroquinolone Prescribing in the Long-Term Care Setting. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 661-663.	2.6	4
12	Imaging Acute Metabolic Changes in Patients with Mild Traumatic Brain Injury Using Hyperpolarized [1- ¹³ C]Pyruvate. <i>IScience</i> , 2020, 23, 101885.	4.1	15
13	Impact of Neostigmine and Sugammadex on Time to Leaving the Operating Room in a Community Hospital. <i>Innovations in Pharmacy</i> , 2020, 11, 9.	0.6	4
14	Vancomycin Area Under the Curve-Guided Dosing and Monitoring: Is the Juice Worth the Squeeze?. <i>Pharmacotherapy</i> , 2020, 40, 1176-1179.	2.6	3
15	1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns. <i>Open Forum Infectious Diseases</i> , 2020, 7, S670-S671.	0.9	0
16	Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1211-1217.	1.0	18
17	Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated Nephrotoxicity. <i>Journal of Clinical Medicine</i> , 2019, 8, 781.	2.4	6
18	Impact of piperacillin/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 343-346.	2.5	11

#	ARTICLE	IF	CITATIONS
19	A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults. <i>Mental Health Clinician</i> , 2019, 9, 280-286.	1.0	6
20	Impact of total body weight on acute kidney injury in patients with gram-negative bacteremia. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 651-654.	3.1	2
21	Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options). <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 139-149.	3.1	2
22	An evaluation of tedizolid for the treatment of MRSA infections. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1489-1494.	1.8	24
23	Impact of total body weight on 30-day mortality in patients with gram-negative bacteremia. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 797-803.	4.4	4
24	Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 552-559.	2.5	11
25	Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 493-508.	3.1	2
26	A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in <i>Staphylococcus aureus</i> skin and soft tissue infections. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 58.	3.8	9
27	Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 674-681.	2.5	12
28	Predictors of community-associated <i>Staphylococcus aureus</i> , methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus</i> skin and soft tissue infections in primary-care settings. <i>Epidemiology and Infection</i> , 2016, 144, 3198-3204.	2.1	10
29	Low-Molecular-Weight Heparin Prophylaxis Dosing. <i>Journal of Pharmacy Technology</i> , 2016, 32, 75-80.	1.0	4
30	Dosing of antifungal agents in obese people. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 257-267.	4.4	31
31	<i>In silico</i> -derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 292-297.	4.7	17
32	Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. <i>Infection and Drug Resistance</i> , 2015, 8, 75.	2.7	12
33	Treatment of community-acquired pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1109-1121.	4.4	4
34	Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World. <i>Current Pharmaceutical Design</i> , 2015, 21, 4748-4751.	1.9	9
35	Dosing of antibacterial agents in obese adults: does one size fit all?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 829-854.	4.4	20
36	Empiric Weight-Based Vancomycin in Intensive Care Unit Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>American Journal of the Medical Sciences</i> , 2014, 348, 371-376.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 653-657.	1.5	7
38	Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2014, 14, 115.	2.9	24
39	Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia: a retrospective cohort study. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 12.	2.4	38
40	Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1666-1674.	1.9	25
41	Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2259-2264.	3.2	47
42	Ethambutol Pharmacokinetic Variability Is Linked to Body Mass in Overweight, Obese, and Extremely Obese People. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1502-1507.	3.2	31
43	Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant <i>Staphylococcus aureus</i> bacteremia: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2012, 12, 104.	2.9	26
44	Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant <i>Acinetobacter</i> ?. <i>Annals of Pharmacotherapy</i> , 2011, 45, 229-240.	1.9	13
45	Evaluation of Chemotherapy-Induced Severe Myelosuppression Incidence in Obese Patients With Capped Dosing. <i>Journal of Oncology Practice</i> , 2011, 7, 13-17.	2.5	31
46	Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5107-5112.	3.2	47
47	Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind. <i>Journal of Intensive Care Medicine</i> , 2010, 25, 259-270.	2.8	12
48	Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?. <i>American Journal of Medicine</i> , 2010, 123, 182.e1-182.e7.	1.5	110
49	Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 95-106.	4.4	67
50	Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances. <i>Pharmacotherapy</i> , 2009, 29, 1468-1481.	2.6	65
51	A Formalized Teaching, Practice, and Research Partnership with the Veterans Affairs North Texas Health Care System: A Model for Advancing Academic Partnerships. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, 141.	2.1	5
52	Acute elevation of triglycerides after initiation of fosamprenavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2008, 2, 398-400.	1.5	1
53	Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity. <i>American Journal of Medicine</i> , 2008, 121, 515-518.	1.5	61
54	Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 605-610.	1.9	106

#	ARTICLE	IF	CITATIONS
55	Impact of Inadequate Empiric Antimicrobial Therapy on Clinical Outcomes of Patients With Escherichia coli or Klebsiella Species Bacteremia. <i>Journal of Pharmacy Practice</i> , 2007, 20, 392-398.	1.0	0
56	Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature. <i>Journal of Pharmacy Practice</i> , 2007, 20, 93-102.	1.0	0
57	Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. <i>Chest</i> , 2007, 132, 1100-1101.	0.8	0
58	Simulated Comparison of the Pharmacodynamics of Ciprofloxacin and Levofloxacin Against Pseudomonas aeruginosa Using Pharmacokinetic Data from Healthy Volunteers and 2002 Minimum Inhibitory Concentration Data. <i>Clinical Therapeutics</i> , 2007, 29, 1421-1427.	2.5	17
59	Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus. <i>Annals of Pharmacotherapy</i> , 2007, 41, 235-244.	1.9	49
60	Atazanavir for the Treatment of Human Immunodeficiency Virus Infection. <i>Pharmacotherapy</i> , 2004, 24, 1732-1747.	2.6	94
61	In vitro activity of parenteral β -lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum β -lactamase producing Klebsiella pneumoniae. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 48-52.	2.5	2
62	In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 41-46.	1.8	70
63	Clinical and Microbiologic Analysis of a Hospital's Extended-Spectrum β -Lactamase-Producing Isolates Over a 2-Year Period. <i>Pharmacotherapy</i> , 2003, 23, 1232-1237.	2.6	54
64	In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 46, 131-137.	1.8	23